Rostami-Far Zahra, Rahmani Khaled, Mansouri Kamran, Khadem Erfan Mohammad Bagher, Shaveisi-Zadeh Farhad, Nikkhoo Bahram
Cellular and Molecular Research Center, Research Institute for Health Development, Kurdistan university of medical science, Sanandaj, Iran.
Liver and Digestive Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran.
Rep Biochem Mol Biol. 2023 Jul;12(2):284-293. doi: 10.61186/rbmb.12.2.284.
The role and regulation mechanisms of the interleukin-6 and 10 (IL6 and IL-10) serum levels and the interaction between CD4+ and CD8+ lymphocytes with SARS-COV-2 IgM and IgG in the context of COVID-19 infection are not fully understood.
This study was conducted on 45 COVID-19 patients and 45 healthy individuals. The IL-6 and IL-10 promoter methylation, IL-6 and IL-10 gene expression, SARS-COV-2 IgM, and IgG antibodies and CD4+ and CD8+ lymphocytes were studied by qMSP-PCR, Real-time PCR, ELISA, and flow cytometry techniques, respectively.
The male ratio and mean age of critically ill patients' group were significantly higher in compared to controls (P< 0.05). IL-6 gene expression and serum levels were significantly increased in patients compared to controls (P=0.002, 0.001), but IL-6 promoter methylation was not significantly decreased in patients (P=0.835). The IL-10 promoter methylation and expression were not different between cases and controls (0.326, 0.455), but serum IL-10 levels were higher in patients (P< 0.001). The CD4+ and CD8+ lymphocytes decreased (P< 0.001) and mean SARS-COV-2 IgG increased (P=0.002) in the patients compared to controls.
The COVID-19 disease result in severe complications in men and elderly. The serum levels of interleukin-6 and 10 increases in COVID-19 infection, and the gene expression of these two interleukins underlying in this increase. The serum levels of IL-6, IL-10 and SARS-COV-2 IgG as well as CD4+ and CD8+ lymphocyte counts should be investigated to monitor patients and predict the course of disease.
在新型冠状病毒肺炎(COVID-19)感染的背景下,白细胞介素-6和10(IL-6和IL-10)血清水平的作用和调节机制以及CD4+和CD8+淋巴细胞与严重急性呼吸综合征冠状病毒2(SARS-CoV-2)IgM和IgG之间的相互作用尚未完全明确。
本研究对45例COVID-19患者和45名健康个体进行。分别采用定量甲基化特异性聚合酶链反应(qMSP-PCR)、实时聚合酶链反应(Real-time PCR)、酶联免疫吸附测定(ELISA)和流式细胞术技术研究IL-6和IL-10启动子甲基化、IL-6和IL-10基因表达、SARS-CoV-2 IgM和IgG抗体以及CD4+和CD8+淋巴细胞。
与对照组相比,危重症患者组的男性比例和平均年龄显著更高(P<0.05)。与对照组相比,患者的IL-6基因表达和血清水平显著升高(P=0.002,0.001),但患者的IL-6启动子甲基化未显著降低(P=0.835)。病例组和对照组之间的IL-10启动子甲基化和表达无差异(0.326,0.455),但患者的血清IL-10水平更高(P<0.001)。与对照组相比,患者的CD4+和CD8+淋巴细胞减少(P<0.001),平均SARS-CoV-2 IgG增加(P=0.002)。
COVID-19疾病在男性和老年人中会导致严重并发症。在COVID-19感染中,白细胞介素-6和10的血清水平升高,且这两种白细胞介素的基因表达是导致这种升高的原因。应检测IL-6、IL-10和SARS-CoV-2 IgG的血清水平以及CD4+和CD8+淋巴细胞计数,以监测患者并预测疾病进程。